Filing summary
Entity and period discrepancy: The supplied filing is Owens & Minor, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, with unaudited quarterly data. It is not an Accendra Health Inc. filing. The filing text does not identify a separate “2013 Q4” annual reporting period; Q4 figures below are the quarter ended December 31, 2013.
Business context and reporting period
Owens & Minor distributes medical and surgical supplies and provides healthcare logistics services. It reports Domestic operations and International operations, the latter consisting primarily of Movianto, acquired in August 2012. Movianto provided a full year of activity in 2013 versus four months in 2012. The 2012 comparative revenue presentation was revised for certain International contracts; the revision reduced revenue and cost of goods sold by $39.8 million each and did not affect earnings or cash flows.
Financial performance and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Net revenue | $9,071.5 million | $8,868.3 million |
| Gross margin | $1,117.1 million; 12.31% | $924.7 million; 10.43% |
| Operating earnings, GAAP | $198.1 million | $196.8 million |
| Net income | $110.9 million | $109.0 million |
| Diluted EPS | $1.76 | $1.72 |
| Operating cash flow | $140.6 million | $218.5 million |
| Capital expenditures | $60.1 million | $39.0 million |
| Cash and cash equivalents at year-end | $101.9 million | $97.9 million |
| Total debt at year-end | $216.2 million | $217.6 million |
Revenue rose 2.3%, while reported operating earnings increased modestly and net income rose 1.7%. The gross-margin increase largely reflected the full-year contribution from Movianto. SG&A increased 26.5% to $863.7 million, partly because of Movianto’s full-year activity and higher Domestic costs. Adjusted operating earnings were $210.5 million, adjusted net income $119.7 million, and adjusted diluted EPS $1.90; these are non-GAAP measures that exclude acquisition-related and exit/realignment charges.
Cash from operations fell by $77.9 million year over year, with management citing working-capital changes, including a 1.3-day increase in DSO and an estimated $33.3 million adverse cash impact. Year-end DSO was 22.1 days, versus 20.8; inventory turnover improved to 10.4 from 10.1. The current ratio, calculated from reported balance-sheet totals, was approximately 1.7 at year-end. The company had no revolver borrowings, $5.0 million of letters of credit outstanding, and $345.0 million available under its $350 million credit facility. Its $200 million senior notes bear 6.35% interest and mature in April 2016.
For Q4 2013, revenue was $2,318.5 million versus $2,294.2 million in Q4 2012; gross margin was $291.3 million versus $270.8 million; net income was $27.9 million versus $24.9 million; and diluted EPS was $0.44 versus $0.39.
Material changes, outlook, risks and unusual items
- Domestic revenue declined 0.5% to $8,688.0 million amid lower healthcare utilization, reduced government purchases, customer and supplier rationalization, and growth that did not fully offset those pressures. International revenue increased to $383.5 million from $136.8 million, reflecting the first full year of Movianto; International operating loss narrowed to $1.4 million from $5.4 million.
- 2013 included $12.4 million of acquisition-related and exit/realignment charges, including $8.9 million for realignment activities. Management expected approximately $2.5 million of additional charges in 2014 for Domestic activities initiated by year-end 2013.
- The company stated that available cash, operating cash flow and revolver capacity should fund working capital, capital expenditures, debt and lease payments, dividends, repurchases and other foreseeable needs. No earnings or revenue guidance was provided in the supplied text. The Board increased the quarterly dividend from $0.24 to $0.25 per share in February 2014 and authorized a new $100 million share-repurchase program through 2017.
- Key exposures include intense price competition and customer bargaining power; GPO and supplier concentration; customer credit risk; healthcare utilization and reimbursement changes; regulatory compliance; international, currency and integration risks; and reliance on information systems, including cybersecurity. Sales to members of Novation, MedAssets and Premier represented about 77% of consolidated revenue; the ten largest domestic suppliers represented about 53%.
- Potential Movianto acquisition and transition claims with the former owner remained under review, and their outcomes could not be estimated. The company reported ordinary-course legal matters and believed pending matters would not materially affect its financial condition or results. Contingent customer obligations of $2.3 million were not accrued because management did not consider payment probable.
- The company was assessing the cash-flow and deferred-tax implications of 2014 IRS regulations affecting inventory vendor charge-backs and tax LIFO calculations. It also disclosed that repatriating foreign earnings could trigger additional taxes, though it did not intend or foresee a need to repatriate them.
KPMG issued unqualified opinions on the consolidated financial statements and internal control over financial reporting; management also concluded disclosure controls were effective.
Important facts for investors to verify
- Confirm the filing identity: the source is Owens & Minor, Inc. (NYSE: OMI), not Accendra Health Inc.
- Separate Movianto’s acquisition-driven revenue and margin contribution from underlying Domestic performance; assess whether International operations can sustain improvement.
- Review the decline in operating cash flow, increased DSO, and working-capital requirements against earnings and capital spending.
- Assess exposure to GPO and supplier concentration, contract renewals, pricing pressure, and customer credit quality.
- Track Movianto transition claims, expected 2014 realignment charges, and the potential tax-LIFO cash-flow effect.
- Evaluate debt maturity and refinancing needs ahead of the 2016 senior-note maturity, alongside dividends and planned repurchases.